Clinical trials: Vulvo Vaginal Atrophy (VVA)
Menopause, Vulvovaginal Atrophy
TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy
The study was designed to evaluate the efficacy and safety of TX-12-004-HR 10 μg in treating moderate to severe symptoms of vaginal atrophy associated with menopause after 14 days of treatment, and to estimate the effect size and…
- Conditions
- Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
- Trial name
- NCT02449902
- Testing
- Estradiol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- TherapeuticsMD
Vulvar Atrophy, Vaginal Atrophy
Clinical and Molecular Study to Evaluate the Effect of the Pixel CO2 Laser (FemiLiftTM) for the Treatment of Vulvo-Vaginal Atrophy
Vulvo Vaginal Atrophy (VVA) refers to the changes in the vaginal and vulvar surfaces that occurs during menopause due to the progressive loss of estrogen.
- Trial name
- VVA PAP POPQ (NCT07024667)
- Testing
- Pixel CO2 Laser for the Treatment of Vulvo-Vaginal Atrophy (VVA)
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hillel Yaffe Medical Center
Vulvovaginal Atrophy
Non-hormonal Medical Device for Treatment of Vulvovaginal Atrophy (VVA) in Post-Menopausal Women
Randomized (1:1), double-blind, sham-controlled, 2-arm parallel study comparing effectiveness and safety of non-hormonal medical device versus sham device to treat VVA in post-menopausal women.
- Trial name
- NCT04887701
- Testing
- Non-hormonal vaginal device therapy
- Where
- 3 sites in Australia
- Volunteers
- 25 people
- Sponsor
- Madorra
Vaginal Dryness
Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause
The objective of this study is to evaluate the efficacy and safety of ospemifene 60 mg once daily (QD) compared with placebo in treatment of vulvo-vaginal atrophy (VVA) due to menopause in women with moderate to severe vaginal…
- Trial name
- NCT02638337
- Testing
- Ospemifene
- Volunteers
- 631 people
- Sponsor
- Shionogi
Vulvo Vaginal Atrophy
Clinical Investigation to Assess Safety and Efficacy of INNEA AQUA in Adult Women With Vulvo-Vaginal Atrophy (VVA)
Clinical investigation to assess safety and efficacy of INNEA AQUA in adult women with Vulvo-Vaginal Atrophy (VVA). To assess the Safety and efficacy of INNEA AQUA
- Trial name
- NCT07367061
- Testing
- product: Innea Aqua vaginal use, arm 2: standard of care
- Where
- 3 sites in Romania
- Volunteers
- 62 people
- Sponsor
- Innate srl
Atrophy, Vaginal Atrophy
Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects
The purpose of this study is to assess the use of the Alma CO2 Pixel FemiLift™ in the treatment of VulvoVaginal Atrophy (VVA) in postmenopausal female subjects.
- Conditions
- Atrophy, Vaginal Atrophy, Genital Diseases, Female
- Trial name
- NCT02747641
- Testing
- Pixel CO2 Laser System
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Alma Lasers Inc.
Vulvo-vaginal Atrophy, Genitourinary Syndrome of Menopause
New Non-Hormonal Treatment by Radiofrequency for Vulvo-Vaginal Atrophy
Vulvo-Vaginal Atrophy (VVA) or Genitourinary Syndrome of Menopause (GSM) is a common and under-reported condition associated with decreased estrogenization of the vaginal tissue The aim of this study is to evaluate safety and…
- Trial name
- ViViA (NCT03857893)
- Testing
- Dynamic Quadripolar Radio-Frequency treatment, pH-Cream
- Where
- 5 sites in Belgium
- Volunteers
- 53 people
- Sponsor
- Serge Rozenberg
Vulvo Vaginal Atrophy, Genitourinary Syndrome of Menopause (GSM)
Treatment of Vulvo-vaginal Atrophy (VVA) Using Vaginal Dilator in Addition to Usual Treatment
This is a randomized, controlled trial aiming to evaluate the effectiveness of adding vaginal dilators to the treatment of vulvovaginal atrophy.
- Conditions
- Vulvo Vaginal Atrophy, Genitourinary Syndrome of Menopause (GSM), Vaginal Atrophy in Breast Cancer Patients, Vaginal Atrophy Patients With GSM
- Trial name
- NCT06828640
- Testing
- vaginal dilators
- Where
- Belgium
- Volunteers
- 160 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Vulvovaginal Atrophy, Menopause
Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
This study will assess the safety and efficacy of a new formulation of vaginal estradiol for the treatment of symptoms of vulvar and vaginal atrophy in postmenopausal women.
- Conditions
- Vulvovaginal Atrophy, Menopause, Dyspareunia, Painful Intercourse
- Trial name
- REJOICE (NCT02253173)
- Testing
- Estradiol
- Where
- 105 sites in United States, Canada
- Volunteers
- 764 people
- Sponsor
- TherapeuticsMD
Vulvo Vaginal Atrophy (VVA)
Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women
Study Objectives: Primary: To assess the safety, tolerability, and systemic pharmacokinetics (PK) of AZU-101 Secondary: To evaluate efficacy of daily vaginal doses of AZU-101 in postmenopausal women on vaginal epithelium
- Trial name
- NCT06197568
- Testing
- Lasofoxifene Tartrate
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Azure Biotech Inc.
Vaginal Atrophy, Vulva; Atrophy
LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2)
This is a randomized controlled trial to evaluate the use of LASER, Micro Ablative radiofrequency and topic promestriene to treat symptoms of vulvovaginal atrophy of women treated for breast cancer.
- Conditions
- Vaginal Atrophy, Vulva; Atrophy, Breast Cancer
- Trial name
- EPMLARF (NCT04081805)
- Testing
- LASER, Micro Ablative Radiofrequency, Promestriene
- Where
- Brazil
- Volunteers
- 195 people
- Sponsor
- Federal University of São Paulo
Vulvovaginal Atrophy
Performance and Safety of Class IIb MD Celegyn® in VVA
The aim of this study is primarily to investigate the performance of Celegyn®, a hyaluronic acid-based vaginal cream (CE marked 0546 medical device), enriched with plant-based ingredients, in comparison with placebo, in promoting…
- Trial name
- NCT03823560
- Testing
- Celegyn®
- Where
- 3 sites in Italy
- Volunteers
- 96 people
- Sponsor
- Nathura S.p.A
Postmenopausal Vulvovaginal Atrophy
A Clinical Study of INTRAROSA® (Prasterone) Vaginal Inserts in Postmenopausal Vulvovaginal Atrophy
This study is a phase III which includes two treatment phases. The phase 1 study is a multi-center, randomized, double-blind, placebo- controlled, parallel group that provide primary efficacy and safety data.
- Trial name
- NCT04982692
- Testing
- intravaginal prasterone
- Where
- China
- Volunteers
- 417 people
- Sponsor
- Lee's Pharmaceutical Limited
Vaginal Atrophy
Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause
The purpose of this study is to confirm the efficacy of intravaginal prasterone (DHEA) on symptoms of vulvovaginal atrophy due to menopause and to collect further data on subjects exposed to intravaginal DHEA in order to meet the…
- Trial name
- NCT02013544
- Testing
- Prasterone (DHEA)
- Where
- 38 sites in United States, Canada
- Volunteers
- 558 people
- Sponsor
- EndoCeutics Inc.
Vulvovaginal Atrophy
Investigation of Efficacy and Tolerability of a Lactic Acid Containing Vaginal Suppository in Post-menopausal Women With VVA
The aim of the study is to investigate the efficacy and tolerability of a lactic acid containing vaginal suppository with respect to the application in post-menopausal women with VVA.
- Trial name
- NCT04222647
- Testing
- WO533
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Vulvovaginal Atrophy, Dyspareunia
Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA
This is an unblinded study to be conducted at a single research center, San Diego Sexual Medicine. Subjects meeting inclusion and exclusion criteria will receive 60 mg ospemifene daily for twenty weeks.
- Trial name
- NCT02784613
- Testing
- Ospemifene
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sue Goldstein
Vaginal Atrophy in Breast Cancer Patients
Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer
The purpose of this study is to confirm the efficacy of intravaginal prasterone (DHEA) on moderate to severe (MS) and most bothersome symptoms (MBS) of vulvovaginal atrophy (VVA) due to natural, surgical or treatment-induced…
- Trial name
- NCT03740945
- Testing
- Prasterone (DHEA)
- Sponsor
- EndoCeutics Inc.